EUVIMED · CrossrefZeitschrift
BioDrugs
ISSN 1173-8804 · Springer Science and Business Media LLC
Neueste Artikel
From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
HLX11: A Pertuzumab Biosimilar
Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk
Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis
Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials
Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects
Correction: Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?
Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes
Risk of Major Cardiovascular Events in Patients with Psoriasis, Psoriatic Arthritis, and/or Other Forms of Spondyloarthritis: A Cohort of 72,291 Biologic New Users
Home Infusion With Recombinant Human α-Glucosidase in Children With Pompe Disease: The Dutch Experience Over 20 Years Across the Spectrum From Classic Infantile to Late-Onset Phenotypes
Recombinant Protein Drugs: A 2025 Update
Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities
Recent Developments in Lipid Nanoparticle-Mediated Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria
Lipid-Lowering RNA Therapeutics for Atherosclerotic Cardiovascular Disease Prevention: A State−of−the−Art Review
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline
Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products
Progress and Challenges in the Treatment of Fabry Disease
The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making
Correction: Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases
Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure
EUVIMED